NCT01068041View on ClinicalTrials.gov

Effects of PH3 in Diabetic Nephropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

July 31, 2014

Study Completion Date

September 30, 2015

Conditions
Diabetic Nephropathy
Interventions
DRUG

PH3

Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient.

Trial Locations (3)

114

Tri-Service General Hospital, Taipei

407

Taichung Veterans General Hospital, Taichung

Unknown

Taipei Veterans General Hospital, Taipei

Sponsors
All Listed Sponsors
lead

PhytoHealth Corporation

INDUSTRY